Skip to content

Addiction: all studies

Page 726 of 857: studies 7,251 to 7,260 of 8,563, newest first. Back to the addiction overview

Research

PHENOMENAL AND ACCESS CONSCIOUSNESS AND THE "HARD" PROBLEM: A VIEW FROM THE DESIGNER STANCE

International Journal of Machine Consciousness June 1, 2010 Aaron Sloman 81 citations

This paper is an attempt to summarise and justify critical comments I have been making over several decades about research on consciousness by philosophers, scientists and engineers. This includes (a) explaining why the concept of “phenomenal consciousness” (P-C), in the sense defined by Ned Block, is semantically flawed and unsuitable as a target for scientific research or machine modelling,...

Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats.

Psychopharmacology June 1, 2010 Christina L Nemeth, Tracie A. Paine, Joseph E Rittiner et al. 102 citations

Disruptions in perception and cognition are characteristic of psychiatric conditions such as schizophrenia. Studies of pharmacological agents that alter perception and cognition in humans might provide a better understanding of the brain substrates of these complex processes. One way to study these states in rodents is with tests that require attention and visual perception for correct...

Metabolism of designer drugs of abuse: an updated review.

Current Drug Metabolism June 1, 2010 Markus R Meyer, Hans H Maurer 112 citations

This paper reviews the metabolism of new designer drugs of abuse that have emerged on the black market during the last years and is an update of a review published in 2005. The presented review contains data concerning the so-called 2C compounds (phenethylamine type) such as 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B), 4-iodo-2,5-dimethoxy-beta-phenethylamine (2C-I),...

DOI: 10.2174/138920010791526042 (opens in new tab) Full text (opens in new tab) Drug metabolism Pharmacokinetics Biotransformation Metabolites +19

Mechanisms mediating the ability of caffeine to influence MDMA (‘Ecstasy’)‐induced hyperthermia in rats

British Journal of Pharmacology May 24, 2010 Natacha Vanattou‐saïfoudine, Ruth Mcnamara, Andrew Harkin 39 citations

Background and purpose: Caffeine exacerbates the hyperthermia associated with an acute exposure to 3,4 methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) in rats. The present study investigated the mechanisms mediating this interaction. Experimental approach: Adult male Sprague‐Dawley rats were treated with caffeine (10 mg·kg −1 ; i.p.) and MDMA (15 mg·kg −1 ; i.p.) alone and in combination. Core...

DOI: 10.1111/j.1476-5381.2010.00660.x (opens in new tab) MDMA Sch-23390 Pharmacology Receptor antagonist +4

Cannabis Use, Psychosis Symptoms Show Strong Link

Psychiatric News May 21, 2010 Mark Moran 2 citations

Back to table of contents Previous article Next article Clinical & Research NewsFull AccessCannabis Use, Psychosis Symptoms Show Strong LinkMark MoranMark MoranSearch for more papers by this authorPublished Online:21 May 2010https://doi.org/10.1176/pn.45.10.psychnews_45_10_028AbstractMarijuana use among individuals with schizophrenia is associated with more severe positive psychotic symptoms...

In Defense of Extended Functionalism

The MIT Press eBooks May 21, 2010 Michael A. Wheeler 115 citations

This chapter aims to clarify the relationship between the extended cognition hypothesis (ExC) and functionalism, and to defend extended functionalism against three of its strongest criticisms. ExC claims that there are conditions under which thinking and thoughts are spatially distributed over the brain, body, and world in such a way that the external factors concerned are rightly accorded...

Are Cannabis Use Disorders Associated with an Earlier Age at Onset of Psychosis? A Study in First Episode Schizophrenia

Schizophrenia Research May 14, 2010 S. Sevy, D. Robinson, B. Napolitano et al.

Introduction The purpose of this study is to determine if an earlier age at onset of positive symptoms in schizophrenia is associated with cannabis use disorders (CUD). Methods 49 first-episode schizophrenia subjects with CUD were compared to 51 first-episode schizophrenia subjects with no substance use disorders for demographic and clinical variables. A multivariate logistic regression was...

Maternal and developmental toxicity of ayahuasca in Wistar rats

Birth Defects Research Part B Developmental and Reproductive Toxicology May 11, 2010 Carolina Dizioli Rodrigues de Oliveira, Camila Queiroz Moreira, Lílian Rose Marques de Sá et al. 44 citations

Abstract INTRODUCTION: Ayahuasca is a psychotropic plant beverage initially used by shamans throughout the Amazon region during traditional religious cult. In recent years, ayahuasca has also been used in ceremonies of a number of modern syncretic religious groups, including pregnant women. However, no documented study has been performed to evaluate the risk of developmental toxicity of...

DOI: 10.1002/bdrb.20244 (opens in new tab) Ayahuasca Developmental toxicity Fetus Physiology +5